August 19th 2024
A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.
A panel of experts discuss the role of odronextamab.
August 12th 2024
August 5th 2024
July 29th 2024
A panel of experts discuss the incidence, severity, and management of AEs associated with CAR Tcell therapy.
A panel of experts discuss risk of secondary malignancies in heavily pre-treated populations.
A panel of experts discusses their individual approaches to bridging therapy in R/R DLBCL for patients eligible for CART
A panel of experts discuss current challenges for use of CAR T in R/R DLBCL.
July 15th 2024
Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.
Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.
Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.
An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.
June 25th 2024
Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.
Medical experts highlight second-line options for treating patients with DLBCL.
February 27th 2024
Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
February 20th 2024
Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.
With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.
February 13th 2024
A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.